Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
PRE 14A
Preliminary proxy
12 Apr 24
8-K
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
1 Apr 24
S-8
Registration of securities for employees
13 Mar 24
S-8
Registration of securities for employees
13 Mar 24
10-K
2023 FY
Annual report
13 Mar 24
8-K
Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update
13 Mar 24
8-K
Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder
25 Jan 24
8-K
Other Events
23 Jan 24
8-K
Liquidia Corporation Announces Updates to Operations Leadership
19 Jan 24
8-K
Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD
8 Jan 24
8-K
Liquidia Corporation Announces $100 Million in New Financings
4 Jan 24
EFFECT
Notice of effectiveness
4 Jan 24
CORRESP
Correspondence with SEC
29 Dec 23
S-3/A
Shelf registration (amended)
28 Dec 23
UPLOAD
Letter from SEC
28 Dec 23
S-3
Shelf registration
22 Dec 23
8-K
Other Events
20 Dec 23
8-K
Unregistered Sales of Equity Securities
14 Dec 23
424B2
Prospectus for primary offering
12 Dec 23
8-K
Liquidia Announces Pricing of Public Offering of Common Stock
12 Dec 23
8-K
Other Events
12 Dec 23
8-K
Regulation FD Disclosure
1 Dec 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update
7 Nov 23
8-K
Other Events
25 Sep 23
8-K
United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office
6 Sep 23
8-K
Regulation FD Disclosure
21 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Liquidia Corporation Reports Second Quarter 2023 Financial Results and Provides Corporate Update
10 Aug 23
8-K
Liquidia Submits Amendment to Add PH-ILD Indication to Tentatively Approved NDA for YUTREPIA™ (treprostinil) Inhalation Powder
27 Jul 23
8-K
U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation
24 Jul 23
8-K
Entry into a Material Definitive Agreement
17 Jul 23
8-K
Regulation FD Disclosure
29 Jun 23
8-K
Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Sustained-Release Inhaled Treprostinil Product in North America
28 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
16 Jun 23
8-K
Entry into a Material Definitive Agreement
8 Jun 23
10-Q
2023 Q1
Quarterly report
8 May 23
Latest ownership filings
4
Rajeev Saggar
23 Apr 24
4
Russell Schundler
16 Apr 24
4
Rajeev Saggar
16 Apr 24
4
Scott Moomaw
16 Apr 24
4
Michael Kaseta
16 Apr 24
4
ROGER JEFFS
16 Apr 24
4
Jason Adair
15 Apr 24
4
Jason Adair
19 Mar 24
4
Russell Schundler
19 Mar 24
4
Scott Moomaw
19 Mar 24
4
Michael Kaseta
19 Mar 24
4
Rajeev Saggar
19 Mar 24
4
ROGER JEFFS
19 Mar 24
4
Scott Moomaw
4 Mar 24
4
Jason Adair
4 Mar 24
SC 13G/A
Manning Paul B
14 Feb 24
SC 13G/A
BlackRock Inc.
7 Feb 24
SC 13G
BlackRock Inc.
31 Jan 24
4
Russell Schundler
16 Jan 24
4
Rajeev Saggar
16 Jan 24
4
Scott Moomaw
16 Jan 24
4
Michael Kaseta
16 Jan 24
4
Jason Adair
16 Jan 24
4
ROGER JEFFS
16 Jan 24
SC 13G
Legend Aggregator, LP
16 Jan 24
4
Jason Adair
20 Dec 23
4
Rajeev Saggar
18 Dec 23
4
ROGER JEFFS
18 Dec 23
4
Paul B Manning
18 Dec 23
4
DAVID EDWARD JOHNSON
14 Dec 23
SC 13D/A
Caligan Partners LP
14 Dec 23
4
Robert A Lippe
5 Dec 23
4
Michael Kaseta
5 Dec 23
4
Scott Moomaw
5 Dec 23
4
Russell Schundler
5 Dec 23
4
Jason Adair
5 Dec 23
4
Arthur S Kirsch
22 Nov 23
4
Jason Adair
20 Sep 23
4
Robert A Lippe
5 Sep 23
4
Scott Moomaw
5 Sep 23